ScripUS President Donald Trump’s ever evolving stance on tariffs may be rattling the world and also has pharma on tenterhooks, but going down that path for generic medicines may be a doubled-edged sword or
ScripAs Donald Trump’s threats to impose tariffs on imported pharmaceuticals increase in intensity, the US president will be pleased to hear that Novartis is expanding its manufacturing and R&D footp
ScripThe number of drug candidates in the pipeline in 2024 rose by its lowest rate so far this decade, with the total at the turn of the year hitting 23,875. The 4.60% increase over 2024’s pipeline figure
ScripMerger-and-acquisition activity in the biopharmaceutical sector had almost nowhere to go but up in the first quarter of 2025, following a historically low quarter in terms of total potential deal valu